Jazz Pharmaceuticals

Investor's Business Daily

Jazz Pharmaceuticals (JAZZ) signed a licensing deal with Concert Pharmaceuticals for exclusive worldwide rights to develop and commercialize deuterium-modified sodium oxybate compounds. Those compounds are the active ingredients in Xyrem, the prescription medicine Jazz markets in the U.S. Shares rose 1.4% to 56.83.

View Comments (0)